{"id":"abbv-453","safety":{"commonSideEffects":[{"rate":"40%","effect":"Neutropenia"},{"rate":"30%","effect":"Thrombocytopenia"},{"rate":"20%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL4297572","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AbbVie's ABBV-453 is a Bruton's tyrosine kinase (BTK) inhibitor, which is a type of kinase inhibitor that targets the BTK enzyme. BTK is involved in the activation of B cells, and its inhibition has been shown to be effective in treating certain types of non-Hodgkin lymphoma.","oneSentence":"BTK inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:51:39.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT06953960","phase":"PHASE1, PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-23","conditions":"Multiple Myeloma","enrollment":130},{"nctId":"NCT06291220","phase":"PHASE1","title":"A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2025-01-27","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":4},{"nctId":"NCT05308654","phase":"PHASE1","title":"A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-05-17","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ABBV-453","genericName":"ABBV-453","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BTK inhibitor Used for Non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}